Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study

Gynecologic Oncology 2026

View at publisher
Authors: Ana Oaknin, William McKean, Marloes van Dongen, Isabelle Ray-Coquard, Jung-Yun Lee, Victor Moreno, Vanda Salutari, Philippe Bedard, V. Boni, Rowan Miller, Jeong-Won Lee, Myong Cheol Lim
+8 more Jean-Sebastien Frenel, Shruti Shah, Francisco Jose Gonzalez Carreras, Antonio Riccio, Sybil Zildjian, Morrys C. Kaisermann, Jennifer Veneris, Stéphanie Lheureux
DOI: 10.1016/j.ygyno.2026.02.027
Cited by: 5

Fields of Study & Subjects

HER2/EGFR in Cancer Research PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment

Publication details

Journal / source
Gynecologic Oncology
Publisher
Elsevier BV
Volume
208
Pages
S454–S455
Publication date
23 April 2026
Language
EN